Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 7, 2013, Pages 612-618

  Ahn, Jeeyun ^a,b,c   Kim, Hyuncheol ^d   Woo, Se Joon ^a,c   Park, Ji Hyun ^c   Park, Sunyoung ^d   Hwang, Duck Jin ^c,e   Park, Kyu Hyung ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Sogang University   (South Korea)

^e Hangil Eye Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BEVACIZUMAB; CEFEPIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; FLUOROURACIL; KETOROLAC TROMETAMOL; METHOTREXATE; RANIBIZUMAB; RITUXIMAB; TRIAMCINOLONE ACETONIDE; TRIFLURIDINE; VANCOMYCIN; VORICONAZOLE;

ANIMAL EXPERIMENT; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; LENSECTOMY; MOLECULAR WEIGHT; NONHUMAN; TRABECULAR MESHWORK; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; INTRAVITREAL INJECTIONS; RABBITS; TISSUE DISTRIBUTION; VITRECTOMY; VITREOUS BODY;

EID: 84883261965     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0009     Document Type: Article

References (40)

1. Aiello, L.P., Avery, R.L., Arrigg, P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994.
2. Spilsbury, K., Garrett, K.L., Shen, W.Y., et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am. J. Pathol. 157:135-144, 2000.
3. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355:1419-1431, 2006.
4. Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology 119:789- 801, 2012.
5. Campochiaro, P.A., Heier, J.S., Feiner, L., et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102-1112 e1, 2010.
6. Martin, D.F., Maguire, M.G., Ying, G.S., et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364:1897-1908, 2011.
7. Nomoto, H., Shiraga, F., Kuno, N., et al. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 50: 4807-4813, 2009.
8. Sinapis, C.I., Routsias, J.G., Sinapis, A.I., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin. Ophthalmol. 5:697-704, 2011.
9. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859, 2007.
10. Doft, B.H., Weiskopf, J., Nilsson-Ehle, I., and Wingard, L.B., Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 92:1601-1605, 1985.
11. Lee, S.S., Ghosn, C., Yu, Z., et al. Vitreous VEGF clearance is increased after vitrectomy. Invest. Ophthalmol. Vis. Sci. 51: 2135-2138, 2010.
12. Chin, H.S., Park, T.S., Moon, Y.S., and Oh, J.H. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 25:556-560, 2005.
13. Jarus, G., Blumenkranz, M., Hernandez, E., and Sossi, N. Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology 92:91-96, 1985.
14. Yanyali, A., Aytug, B., Horozoglu, F., and Nohutcu, A.F. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am. J. Ophthalmol. 144:124-126, 2007.
15. Kakinoki, M., Sawada, O., Sawada, T., et al. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest. Ophthalmol. Vis. Sci. 53:5877-5880, 2012.
16. Christoforidis, J.B., Williams, M.M., Wang, J., et al. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 33:946-952, 2013.
17. Bakri, S.J., Snyder, M.R., Pulido, J.S., et al. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26:519-522, 2006.
18. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179-2182, 2007.
19. Coco, R.M., Lopez, M.I., Pastor, J.C., and Nozal, M.J. Pharmacokinetics of intravitreal vancomycin in normal and infected rabbit eyes. J. Ocul. Pharmacol. Ther. 14:555-563, 1998.
20. Schindler, R.H., Chandler, D., Thresher, R., and Machemer, R. The clearance of intravitreal triamcinolone acetonide. Am. J. Ophthalmol. 93:415-417, 1982.
21. Wang, M., Liu, W., Lu, Q., et al. Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. Neurosurgery 2012. [Epub ahead of print] DOI: 10.1097/IAE.0b013e3182576d1d
22. Knudsen, L.L., Dissing, T., Hansen, M.N., and Nielsen-Kudsk, F. Ocular fluorescein kinetics before and after vitrectomy on swine. Graefes. Arch. Clin. Exp. Ophthalmol. 239:832-839, 2001.
23. Maurice, D.M. Injection of drugs into the vitreous body. In: Leopold, I.H., Burns, R.P., eds. Symposium on Ocular Therapy. New York: John Wiley & Sons, Inc.; 1976; p. 59-72.
24. Laude, A., Tan, L.E, Wilson, C.G., et al. Intravitreal therapy for neovascular age-related macular degeneration and interindividual variations in vitreous pharmacokinetics. Prog. Retin. Eye. Res. 29:466-475, 2010.
25. Heiduschka, P., Fietz, H., Hofmeister, S., et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest. Ophthalmol. Vis. Sci. 48:2814-2823, 2007.
26. Gaudreault, J., Fei, D., Rusit, J., et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46:726-733, 2005.
27. Miura, Y., Uematsu, M., Teshima, M., et al. Injection site and pharmacokinetics after intravitreal injection of immunoglobulin G. J. Ocul. Pharmacol. Ther. 27:35-41, 2011.
28. Batman, C., and Ozdamar, Y. The effect of bevacizumab for anterior segment neovascularization after silicone oil removal in eyes with previous vitreoretinal surgery. Eye (Lond) 24:1243-1246, 2010.
29. Miki, A., Oshima, Y., Otori, Y., et al. One-year results of intravitreal bevacizumab as an adjunct to trabeculectomy for neovascular glaucoma in eyes with previous vitrectomy. Eye (Lond) 25:658-659, 2011.
30. Zhu, Q., Ziemssen, F., Henke-Fahle, S., Tatar, O., Szurman, P., Aisenbrey, S., Schneiderhan-Marra, N., Xu, X., and Grisanti, S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115:1750-1755, 1755 e1751, 2008.
31. Krohne, T.U., Eter, N., Holz, F.G., andMeyer, C.H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. 146:508-512, 2008.
32. Meyer, C.H., Krohne, T.U., and Holz, F.G. Intraocular pharmacokinetics after a single intravitreal injection of 1.5mg versus 3.0mg of bevacizumab in humans. Retina 31:1877-1884, 2011.
33. Kim, H., Csaky, K.G., Chan, C.C., Bungay, P.M., Lutz, R.J., Dedrick, R.L., Yuan, P., Rosenberg, J., Grillo-Lopez, A.J., Wilson, W.H., and Robinson, M.R. The pharmacokinetics of rituximab following an intravitreal injection. Exp. Eye Res. 82:760-766, 2006.
34. Gaudreault, J., Fei, D., Beyer, J.C., Ryan, A., Rangell, L., Shiu, V., and Damico, L.A. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 27:1260-1266, 2007.
35. Krohne, T.U., Liu, Z., Holz, F.G., and Meyer, C.H. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am. J. Ophthalmol. 154:682-686, 2012.
36. Barza, M., Lynch, E., and Baum, J.L. Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits. Arch. Ophthalmol. 111:121-125, 1993.
37. Ozkan, E.B., Ozcan, A.A., and Alparslan, N. Intravitreal injection of methotrexate in an experimental rabbit model: determination of pharmacokinetics. Indian J. Ophthalmol. 59:197-200, 2011.
38. Shen, Y.C., Wang, M.Y., Wang, C.Y., Tsai, T.C., Tsai, H.Y., Lee, Y.F., and Wei, L.C. Clearance of intravitreal voriconazole. Invest. Ophthalmol. Vis. Sci. 48:2238-2241, 2007.
39. Pearson, P.A., Hainsworth, D.P., and Ashton, P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina 13:326-330, 1993.
40. Pang, M.P., Branchflower, R.V., Chang, A.T., Peyman, G.A., Blatt, H., and Minatoya, H.K. Half-life and vitreous clearance of trifluorothymidine after intravitreal injection in the rabbit eye. Can. J. Ophthalmol. 27:6-9, 1992.